This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William J. O'Connor, MB, MRCPI
Department of Dermatology Mayo Clinic 200 First St SW Rochester, MN 55905

Gillian M. Murphy, MD, FRCPI
Dublin, Ireland

Arch Dermatol. 1997;133(5):655-656.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We welcome the study by Wolkenstein et al¹ of the usefulness of screening investigations in neurofibromatosis type 1 (NF1). Because of the high incidence of NF1 (up to 1 case in 2500 births), this work is of great practical significance for the practicing dermatologist. We have performed similar work² to evaluate the necessity of screening for the presence of optic glioma at the time of diagnosis of NF1 (Figure 1). In this study, our aims were to define the prevalence and clinical significance of optic gliomas in patients presenting to the Dermatology Outpatient Department, Beaumont Hospital, Dublin, Ireland, to determine what proportion of gliomas were symptomatic and to evaluate screening modalities. In addition, the patients with optic gliomas detected by screening were followed up closely for 5 years.

Standard diagnostic criteria for NF1 were applied.¹ Any symptoms of diplopia, headache, seizure, neurologic deficit, or visual deterioration were . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?